Foghorn Therapeutics, Inc. ( (FHTX) ) has released its Q3 earnings. Here is a breakdown of the information Foghorn Therapeutics, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Foghorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing new medicines targeting genetic dependencies within the chromatin regulatory system, utilizing its proprietary Gene Traffic Control platform. The company operates in the biopharmaceutical industry and is headquartered in Cambridge, Massachusetts.
In its latest earnings report for the quarter ended September 30, 2025, Foghorn Therapeutics reported a net loss of $15.8 million, which is an improvement from the $19.1 million loss in the same period last year. The company generated $8.2 million in collaboration revenue, primarily from its ongoing partnership with Eli Lilly and Company.
Key financial metrics from the report include a decrease in operating expenses to $26.7 million from $31.7 million in the previous year, driven by reduced research and development costs. Despite the losses, Foghorn’s cash and cash equivalents increased to $89.3 million, supported by proceeds from previous stock offerings. The company also reported total assets of $205 million and a stockholders’ deficit of $89.7 million.
Looking ahead, Foghorn Therapeutics remains focused on advancing its product candidates through clinical development, leveraging its collaboration with Eli Lilly, and exploring additional strategic partnerships. The company anticipates continued operating losses as it invests in research and development but is committed to achieving long-term growth and value creation.